

26 November 2025

BXN ships Australian-Made MDMA batch to Victorian Government hospital clinical trial

- Second GMP MDMA shipment dispatched this week to Eastern Health (Victorian Government) – less than two weeks after the landmark first Australian-made batch shipment
- Supplying a ground-breaking public health clinical trial targeting treatment-resistant PTSD co-occurring with borderline personality disorder
- Demonstrates surging clinical demand and positions Breathe Life Sciences as Australia's first domestic supplier of pharmaceutical-grade MDMA and psilocybin

Bioxyne Limited (ASX: BXN) ("Bioxyne" or "the Company") is pleased to announce that its wholly owned subsidiary, Breathe Life Sciences (BLS), has dispatched its second shipment of Australian-manufactured GMP MDMA capsules to the Victorian Government's Eastern Health department.

The shipment will support a Victorian public health system clinical trial investigating MDMA-assisted psychotherapy for patients with co-occurring post-traumatic stress disorder (PTSD) and borderline personality disorder (BPD) – a particularly treatment-resistant dual diagnosis.

This is the first MDMA shipment to Eastern Health, following the Company's landmark announcement earlier this month¹.

Chief Executive Officer Sam Watson commented:

"Delivering our second shipment in under two weeks demonstrates the reliability and scalability of our Australian GMP facility. We are proud to be directly supporting Victorian Government-led clinical research into MDMA-assisted therapy, bringing genuine hope to patients with treatment-resistant PTSD. With additional orders in the pipeline across Australia and increasing international interest, this segment is quickly becoming a material growth driver alongside our core medicinal cannabis and consumer health businesses."

MDMA Clinical Trial Background

The controlled before-and-after study, conducted at Box Hill Hospital and associated Eastern Health sites aims:

- To determine the feasibility and acceptability of delivering MDMA-assisted psychotherapy within the Victorian public mental health system
- To assess early indicators of improved efficacy and reduced treatment time for patients with co-occurring PTSD (or complex-PTSD) and BPD

¹ BXN ASX Announcement, Bioxyne releases Australian made GMP MDMA capsules for supply to Clinical Trials in Victoria and to Authorised Prescriber dispensing in Queensland, dated 11 November 2025



- To generate preliminary public cost-benefit data and safety insights that could support a larger randomised controlled trial

Approximately 12% of Australians will experience PTSD in their lifetime, with co-occurring BPD significantly complicating recovery. The global psychedelic drugs market is forecast to reach A\$14 billion by 2032 as acceptance of psychedelic-assisted therapies grows².

Approved by the Board of Bioxyne Limited for release to the ASX.

For further information, please contact:

Bioxyne Limited

Sam Watson
Chief Executive Officer
info@bioxyne.com

NWR Communications

Melissa Tempa
Media & Investor Relations
melissa@nwrcommunications.com.au

About Bioxyne Limited

Bioxyne Limited is an Australian pharmaceutical company focused on the development and commercialisation of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into the production of psychedelic compounds for therapeutic use.

About Breathe Life Sciences

Breathe Life Sciences ("BLS") is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company's corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, health products, and prescription-only cannabis medicines.
- b) Contract drug manufacturing and white label manufacturing of scheduled medicines, therapeutic goods, medical devices, consumer health products, and active pharmaceutical ingredients. BLS manufactures over 200 of Australia's medicinal cannabis brands.

² https://www.marketresearchfuture.com/reports/post-traumatic-stress-disorder-market-8376?utm_source=chatgpt.com



c) Import, export, and wholesale of active pharmaceutical ingredients, starting materials, patient-ready medicinal products, and/ or consumer health products in Australia, Japan, UK, USA and Europe.

d) Research and development of novel medicines.

e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®

- United Kingdom: drwatsoncbd.com
- UK / EU: breathelifesciences.com

Corporate: bioxyme.com

Australia: bls.com.au

International: breathelifesciences.com

